Some of the serum proteins which bind to heparin and contribute to the pH 5.57 "heparin binding capacity" of human serum are glycoproteins; those from cystic fibrosis serum were found to be 27% higher in fucose (methylpentose) content, 27% lower in sialic acid content, and 31% lower in hexose content when compared to heparin-precipitated serum glycoproteins from normal control subjects. Hexosamine content of the heparin-precipitated serum glycoproteins was the same. Results of this preliminary investigation indicate that altered carbohydrate composition in serum glycoproteins may affect significantly their heparin binding capacity.
Speculation
The glycoprotein biosynthetic mechanism in cystic fibrosis is genetically altered and produces glycoproteins of abnormal carbohydrate composition which combine with normal, acidic, glycosaminoglycans to form insoluble, viscous complexes that hinder normal cellular and subcellular transport mechanisms and metabolic processes.
Cystic fibrosis, a generalized, autosomal recessive disease, in which there is usually a dysfunction of all or most of the exocrine glands of the body, occurs in approximately 1 in 2000 live births. Comprehensive reviews appear in the literature (8, 10, 21, 23, 44, 50, 56) citing numerous efforts directed at discovering the basic defect(s) responsible for the disease.
In a recent report (49), we described a simple method which we used to demonstrate that individual sera from subjects with cystic fibrosis had a much higher capacity for the in vitro binding of heparin than did sera from a group of healthy controls. We suggested that the increased capacity of serum proteins to bind heparin would help to explain the subnormal rise in plasma activity of lipoprotein lipase (EC 3.1.1.3) observed by Slack et al. (54) in fibrocystic individuals after heparin was administered.
Previous research in cystic fibrosis involving in vitro techniques also suggested unique heparin-protein binding interactions; it was observed that heparin could negate or neutralize abnormalities which the reported "cystic fibrosis factor(s)" (15, 41, 56) produced in sodium transport (42) and ciliary motility (28) (29) (30) . Based upon previous theories that serum protein anomalies in cystic fibrosis (1, 61) probably result from differences in glycoproteins (60), we decided to use our new in vitro technique to investigate if glycoprotein differences were implicated in heparin-protein binding interaction.
This paper describes a preliminary investigation the results of which suggest that glycoproteins of abnormal carbohydrate composition are responsible for our observations of an increased heparin-binding-capacity of serum protein(s) in cystic fibrosis (49) .
SUBJECTS
Ten patients, five males and five females, ages 13-36 yr with a diagnosis of cystic fibrosis confirmed by clinical and laboratory evaluations were included in this study. The severity of their conditions was evaluated at 6 week intervals: three were classified as having mild disease progression, two as moderate, and five as severe. Twelve healthy individuals, six males and six females, ranging in age from 23-44 yr served as controls. In this preliminary investigation, no attempt was made to match the age or sex of cystic fibrosis patients with controls, although a matching technique might eliminate potential biologic biases.
SERUM
Venous blood samples (nonfasting) were taken from the cystic fibrosis patients and from the normal controls after receipt of informed consent (65) . The blood was allowed to clot at room teperature for 1 hr. After centrifugation, the serum was removed and stored in plastic tubes (Falcon # 2027, Falcon Plastics, Oxnard, Ca.) at 4°C (for no longer than 48 hr) until the described analyses were performed.
CHEMICALS
All chemicals employed in the methodologies described were of reagent quality unless otherwise specified.
HEPARIN-BOUND PROTEIN ISOLATION
Serum proteins were precipitated with heparin at pH 5.57, and the protein-heparin precipitate redissolved as previously described (49) . PROTEIN 
ANALYSIS
Protein in serum (total protein) and in the precipitated heparinprotein pellet was determined by the method of Lowry et al. (39) , using crystalline bovine albumin (Calbiochem, Ldolla, Ca.) as standard. In general, 10 p1 of a (1:20) dilution of serum in normal saline or 10 pl of the 2.20 ml redissolved "pellet solution" (49) contained sufficient protein for analysis when albumin standards ranged from 20-100 pg of protein.
HEPARIN QUANTITATION
Heparin was determined indirectly by measuring the uronic acid content of the 2.20 ml pellet solution. Uronic acid was determined by the carbazole method (24) as modified by Bitter and Muir (6) using D-Glucuronic Acid Lactone as standard (Sigma Chemical Co., St. Louis, MO). The heparin used throughout this study was determined to contain 30.0% uronic acid by weight.
CARBOHYDRATE ANALYSES
Total protein-bound hexose, hexosamine, fucose (methylpentose), and sialic acid were determined in whole serum and in the heparin-precipitated proteins by methods described by Winzler (62 (12) (13) (14) as modified by Winzler (62) using Diphenylamine (Mallinkrodt Chemical Works, St. Louis, MO) with N-Acetylneuraminic Acid (Calbiochem, LaJolla, CA) as standard. In general, 200 p1 of whole serum and 400 pl of the pellet solution were sufficient for analysis using 20-200 pg range of Nacetylneuraminic acid (sialic acid) as standard.
Method Notes.
(1) Initial alcoholic precipitation of proteins was eliminated for samples of the pellet solution, i.e., specifically for total protein-bound hexose, fucose, and hexosamine. (2) The heparin used throughout this study contained 6.79% by weight hexose and 13.16% by weight hexosamine. Consequently, the heparin contribution to values of total hexose and hexosamine in the heparin-protein precipitate was subtracted from the total to yield hexose and hexosamine bound only to the precipitated proteins. (3) Heparin gave no reactivity in the methods employed for fucose and sialic acid, nor did it interfere or react in the assay for protein. (4) While fucose is present as L-fucose in human glycoproteins, the methodology employed for fucose determination yields the same result when either the D-or L-isomers of fucose are used as standard (62) .
Analysis of the Data. Statistical analyses for means, SD, linear regression analysis by method of least squares, and I tests for the significance of the difference between two sample means were performed using an Olivetti Underwood Programma 101 desktop computer (Olivetti Underwood Corp., One Park Ave., New York, NY). Table 1 presents data obtained from analyses for protein, heparin, and the protein:heparin ratio by weight as determined in the precipitate from 1 ml of serum for cystic fibrosis patients and from control subjects. More protein and proportionately more heparin (Table 1) are precipitated from 1 ml of serum from cystic fibrosis individuals than from control subjects. The weight ratio by which protein and heparin combine to precipitate from the buffered solution (Table I) , is significantly different between the two groups. An average 25% less protein combines per unit weight of heparin to precipitate from solution for the cystic fibrosis group than for the controls.
RESULTS
Results of analyses of the total serum proteins for some individual carbohydrate constituents of serum glycoproteins, specifically, hexose, hexosamine, fucose, and sialic acid are presented in Table  2 . Only the carbohydrate moiety hexosamine is increased significantly in the cystic fibrosis group relative to the control group, and protein-bound hexosamine is known to be increased in chronic pulmonary and liver disease (55, 63) .
Results for the carbohydrate composition of the precipitated serum proteins and their relation to the carbohydrate composition of the total serum proteins are presented in Tables 3, 4 , and 5. Only hexosamine differences in the precipitated proteins were expected because only hexosamine in the total serum proteins was observed to be increased in the cystic fibrosis subjects (Table 2) . However, while the total serum protein-bound hexosamine is increased for the cystic fibrosis group (Table 3) , the quantity of hexosamine precipitated (Table 3) , and the hexosamine composition of the precipitated proteins as a weight per cent (Table 3) is decreased compared to normal controls.
No differences in hexose, fucose, or sialic acid composition of the precipitated proteins were expected between the cystic fibrosis and control groups as judged from the total serum protein carbohydrate values (Table 2 ). However, comparisons of the fucose and sialic acid composition (Table 4 ) and of the fucose and hexose composition (Table 5 ) of the precipitated proteins showed highly significant differences. The quantity of fucose precipitated (Table  4) , and the fucose composition of the precipitated proteins as weight percent (Table 4) were significantly increased for the cystic fibrosis group. The quantity of the sialic acid precipitated (Table  4) and the sialic acid composition of the precipitated proteins (Table 4) generally was decreased for the cystic fibrosis group, although not significantly. The ratio of fucose to hexose found in the total serum proteins of the two groups was compared (Table   5 ), no significant difference was found, but comparisons of the fucose composition (Table 4 ) and the hexose composition (Table  5 ) of the precipitated proteins showed highly significant differences between the two groups. Cystic fibrosis precipitated proteins were increased in fucose content and decreased in hexose content when compared to controls. Consequently, the ratio of the fucose/ hexose composition of the precipitated proteins (Table 5) is greatly increased for the cystic fibrosis group and is even more highly significant.
DISCUSSION
Previous cystic fibrosis research reports indicate that glycoprotein biosynthesis is generally altered in most, if not all, cell types which synthesize glycoproteins, whether for secretory purposes, or for normal cellular growth, maintenance, and repair. In particular, the incorporation of the methylpentose sugar, fucose, seems aberrant.
Altered fucose metabolism in cystic fibrosis was first suggested by Dische et al. (25) who showed that, in a certain ethanol benzene insoluble fraction of glycoproteins from duodenal mucus secre-tions from patients with cystic fibrosis, the ratio of fucose to sialic acid and to total protein was higher than in the other fractions from the same duodenal mucus sample. Dische et al. (25) proposed that the abnormal shift in sugars (fucose increase, sialic acid decrease) might lead to an increase in molecular size and, thus, to decreased solubility and increased viscosity. This same glycoprotein fraction was previously shown to be resistant to the digestion action of trypsin (21) . This finding may also have implications for the works of Wilson and Fudenberg (60) , who demonstrated a deficient proteolytic cleavage of az-macroglobulin in cystic fibrosis plasma, and for Shapira et al. (53) who demonstrated an abnormal complex between trypsin-like proteases and cystic fibrosis azmacroglobulin, a serum glycoprotein known to contain fucose (55) .
There is evidence that salivary glands produce, in addition to their specific secretions, glycoproteins similar to those in mucus (26) . Recently, Ghua et al. (32) have shown that there is a greater incorporation of fucose by fucosyl transferase into acceptor glycoproteins prepared from cystic fibrosis saliva than those prepared from normal saliva. Additional preliminary isoelectric focusing studies of the acceptor glycoproteins suggest an altered apoglycoprotein (peptide) structure, with, perhaps, increased binding-sites for fucose terminated oligo-or polysaccharides. These results, although preliminary, suggest a genetic defect in the control of production of the peptide portion of the glycoprotein molecule, creating an abnormal proportion of fucose-terminated oligo-or polysaccharides in the presence of a normal activity level of fucosyl transferase (32) .
Glycoprotein biosynthesis in cultured fibroblasts from skin of cystic fibrosis patients has also been extensively studied (21, 23) . While some of the investigations have not produced consistent, identifiable differences in glycoprotein metabolism by fibroblasts in general (3, 1 l), some investigators have demonstrated differences which may directly affect glycoprotein biosynthesis or, be the result of an abnormality in the glycoprotein biosynthetic mechanism. Novak and Abell (47) have shown that fibroblasts from skin of cystic fibrosis patients secrete greater amounts of low molecular weight, fucose-containing glycopeptides as components of soluble glycoproteins. They found that normal fibroblasts preferentially incorporate fucose into higher molecular weight glycopeptides. This result, that there is an increased incorporation of fucose into low molecular weight glycopeptides, is consistent with the earlier work of Dische et al. (25) , the finding of an increased ratio of fuwse to total protein (total peptides).
Other evidence from fibrobla3 research, recently published by Rao et al. (Sl) , supports an abnormality in the glycoprotein biosynthetic mechanism. They showed that the activity of an enzyme which incorporates galactose into the carbohydrate chains of glycoproteins is increased, specifically UDP-ga1actose:glycoprotein galactosyl transferase. What exact relationship this finding has to the incorporation of fucose into fibroblast-secreted glycoproteins remains to be investigated. However, because fucose occurs in glycoproteins as a terminal sugar of carbohydrate side chains, the production of an increased number of shorter chain (lower molecular weight) carbohydrate side chains might allow for increased fucose incorporation. This finding, then, would be consistent with the work of Novak and Abell (47) .
Additional evidence to support an abnormality in the glycoprotein biosynthetic mechanism at the subcellular level in cystic fibrosis was obtained from studies on lung tissue. Louisot and Leurat (38) demonstrated a hyperactivity of several glycosyl transferases at the microsomic levels in lung tissue, particularly in fucosyl transferase. If fucosyl transferase were hyperactive in all cell types producing glycoproteins in cystic fibrosis, it would, then, account for the increased incorporation of fucose, especially if the peptide portions of cystic fibrosis glycoproteins are biosynthesized with increased numbers of acceptor sites for fucose-terminated carbohydrate side chains (32) and/or increased amounts of fucoseterminated carbohydrate side chains are biosynthesized.
Previously, serum glycoprotein abnormalities have only been suggested by the work of Wilson et al. (61) on az-macroglobulin, a macroglobulin whose carbohydrate composition and amino acid sequences are known (55) . Using isoelectric focusing techniques, Wilson and Fudenberg (60) demonstrated that a*-macroglobulin, a fucose-containing glycoprotein, from cystic fibrosis patient serum was not proteolytically cleaved to the same degree by enzymes which would break down az-macroglobulin from normal control serum. This observation is very interesting considering the observation of Dische et al. (21) that the mucous glycoprotein fraction of increased fucose content was also resistent to proteolytic cleavage by trypsin. Wilson and Fudenberg (60) did not determine the fucose content of the a*-macroglobulin, however, so attempts to correlate reduced proteolytic degradation with increased fucose content in armacroglobulin are premature.
Our investigation of serum glycoproteins in cystic fibrosis also supports the concept of generally altered glycoprotein biosynthesis in cystic fibrosis. Our results concerning the carbohydrate composition of proteins in sera from cystic fibrosis subjects precipitated by heparin in an in vitro system indicate that these proteins are, at least in part, glycoproteins which are significantly different in cystic fibrosis subjects in their hexose, fucose, and sialic acid content and in overall proportions of those carbohydrates which are bound to the prote& peptide moiety (Tables 3-5 ). In general, precipitated cystic fibrosis glycoproteins, when compared to the precipitated normal glycoproteins, are 27% higher in fucose content, 27% lower in sialic acid content, and are 3 1% lower in hexose content (refer to Tables 4 and 5 ). The exact identity of the glycoproteins which are precipitated remains to be deiermined, but the collective increase in the fucose content of the precipitated glycoproteins and the significant increase in the ratio bf fu'cose to protein and to hexose and sialic acid supports the hypothesis that at least one or more serum glycoproteins is the product of a biosynthetic mechanism incorporating increasing amounts of fucose into glycoprotein.
While salivary, mucus, fibroblast, and serum glycoproteins are produced by different cell types and have distinctive physicochemical compositions, the biochemical synthetic processes involved in their production are believed to occur in similar subcellular microsomal sites with similar enzymatic systems (32, 55) . A recently proposed pathway for plasma glycoprotein biosynthesis (46) provides evidence that glycoproteins are synthesized sequentially at three different subcellular sites: 1) the membrane-bound ribosomes, 2) the lumen of the endoplasmic reticulum, and 3) at the golgi apparatus. The biosynthetic reactions are carried out by enzymes strongly bound to the membranes. The final structure of the glycoprotein molecule is determined by specific glycosyltransferase enzymes which add specific carbohydrates (e.g., hexose, fucose, hexosamines, sialic acids) to the glycoprotein in amounts regulated by relative enzyme adtivity aLd-specific carbohydrate nucleotide substrate availability. The completed glycoproteins are -. . packed into secretory vesicles-in the golgi apparatus and transferred to the blood after fusion of the vesicles with the cell membrane (5, 46, 57) . This process is thought to be similar in other cell types.
The biosynthesis of glycoproteins is under genetic regulation of two types. Direct genetic regulation occurs during the assembly of the glycoprotein peptide moiety; indirect genetic regulation occurs during assembly and attachment of the carbohydrate chain moieties to the peptide portion of the glycoprotein molecule (46, 55) . Interactions of variable complexity between single defective alleles or among multiple defective alleles which code for the assembly of the peptide portion of glycoproteins (direct regulation) and of the enzymes involved in assembly and attachment of the carbohydrate chain moieties to the giycoprotein peptide structure(s) (indirect regulation) may give rise to glycoproteins of abnormal composition, particularly increased in fucose content.
Our results demonstrate that certain serum proteins from cystic fibrosis serum, at least some of which are glycoproteins of abnormal composition, have a higher than normal capacity to bind and combine with heparin, an acidic glycosaminoglycan (Fig. 1) . The increased fucose content (Fig. 2) and lowered sialic acid and hexose content (Fig. 3) in these not-yet-identified proteins may cirrhosis) are thought to be secondary to this kind of obstruction 22. DiSant'Agnese, P. A., Dische, Z., and Danilezenko. A,: Phvsicochemical differ- (21) . ~& a u s e of ;he complex pheiotype expressions of cystic fibrosis (16) generally observed as a heterogeneity of clinical presentations (especially characterized by individuals with pulmonary difficulties, others mainly with gastrointestinal problems, those with multisystemic involvement, and those few with little difficulty other than sweat electrolyte abnormalities), the resultant clinical manifestations of cystic fibrosis (17) could be related genetically to defects in the glycoprotein biosynthetic mechanisms.
We believe that research in fucose incorporation into glycoproteins in cystic fibrosis should be intensified in light of our current findings and the previous findings of other investigators who have studied glycoproteins in cystic fibrosis. Perhaps the finding of an increased heparin affinity by glycoproteins of increased fucose content will prove to be a useful research tool for preliminary isolations of glycoproteins of increased fucose content, which can then be purified by other techniques and studied for their effects on normal cellular secretory functions and plasma membrane functions (ion transport mechanisms) which are known to be abnormal in cystic fibrosis (21, 23, 35, 36, 41) . We plan to pursue additional studies with the serum glycoprotein fraction of increased fucose content and increased heparin binding capacity to identify and fully characterize the total number and different kinds of proteins precipitated by heparin at pH 5.57 in our in vitro system, especially with regard to the exact amino acid and carbohydrate composition and their sequences, the physical structure of those proteins, and any possible immunologic differences that may exist between the cystic fibrosis and normal heparin-precipitated poteins.
